Merrimack CEO Resigns, Company Cuts 22 Percent of Workforce

Cancer drug developer Merrimack Pharmaceuticals Inc. is cutting nearly a quarter of its workforce and searching for a new CEO after announcing a restructuring to eliminate more than $200 million in costs